RD Fund participates in USD115m SalioGen Therapeutics Series B round
The RD Fund (Retinal Degeneration Fund) – the venture arm of the Foundation Fighting Blindness – has invested in a USD115 million syndicated Series B round for SalioGen Therapeutics to support the company’s preclinical research into novel genetic medicines for inherited retinal disorders.